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Abstract: The steady improvement and optimization of transdermal permeation is a constant and
challenging pharmaceutical task. In this study the influence of poly(lactide-co-glycolide) (PLGA)
nanoparticles on the dermal permeation of the anti-inflammatory drug flufenamic acid (FFA) was
investigated. For this aim, different vehicles under non-buffered and buffered conditions and different
skin models (human heat separated epidermis and reconstructed human epidermis equivalents)
were tested. Permeation experiments were performed using static Franz diffusion cells under infinite
dosing conditions. Already the presence of drug-free nanoparticles increased drug permeation
across the skin. Drug permeation was even enhanced when applying drug-loaded nanoparticles. In
contrast, buffered vehicles with different pH values (pH 5.4–7.4) revealed the influence of the pH
on the permeation of FFA. The change of the surrounding pH of the biodegradable nanoparticulate
system was demonstrated and visualized using pH-sensitive fluorescent probes. While a potential
contribution of hair follicles could be ruled out, our data suggest that the enhanced permeation of
FFA through human skin in the presence of PLGA nanoparticles is mediated by a locally decreased
pH during hydrolytic degradation of this polymer. This hypothesis is supported by the observation
that skin permeation of the weak base caffeine was not affected.
Keywords: PLGA; polymer nanoparticles; pH effects; human skin; permeation; penetration
1. Introduction
The skin, due to the structure and composition of the stratum corneum, provides
a highly impermeable barrier of the human body against the environment. However,
the same features limit the dermal absorption of active compounds. Therefore, several
strategies to improve the transdermal delivery of active pharmaceutical ingredients have
been investigated e.g., by means of physical/mechanical enhancement, by supersaturated
formulations, ionto- and sonophoresis, electroporation, microneedles, chemical penetra-
tion enhancers and nanosized drug delivery systems [1,2]. Nowadays, nanosized drug
delivery systems have gained a broad attention for use in dermal/transdermal delivery
due to the possibility of delivering the active compound in a controlled manner to or
across skin [3–6]. During the last decades, polymer-based biodegradable nanoparticles
in particular have attracted considerable attention as drug delivery vehicles for which
both enhanced penetration [7,8] as well as prolonged release [9] have been reported. In
comparison to other drugs in solution, the permeation of the anti-inflammatory drug flufe-
namic acid encapsulated into poly(lactide-co-glycolide) nanoparticles (PLGA-NP) through
human skin was improved [7]. Moreover, the same effect occurred by simply adding
drug-free nanoparticles (PLGA-DF-NP) to FFA in solution [7]. In contrast to reports of
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Riviere et al. concerning fullerene nanoparticles [10] we could not show any absorption for
PLGA-NP by the skin using multiphoton microscopy [11]. The nanoparticles accumulated
within dermatoglyphs and did not enter the Stratum corneum. Consequently, enhanced
follicular transport [12,13] could potentially be responsible for this. Therefore, follicle-free
reconstructed skin equivalents were used to address their influence. Furthermore, the
known hydrolytic degradation of PLGA into lactic and glycolic acid and the accompanying
pH change should also be investigated [14]. In this context, potential pH effects of the
nanoparticles on skin permeation were studied at buffered and non-buffered conditions.
Furthermore, a pH-sensitive fluorescent dye was used to monitor the pH within the mi-
croenvironment of PLGA particles. To prove that the change of ionization of flufenamic
acid (log P = 4.88 [15], pKa = 3.9 [16], MW 281.1 [17]) is due to the change of pH, an
additional experiment with caffeine (log P = −0.08, pKa 14.0 [18], MW 194.2 [17]) was
performed.
2. Materials and Methods
2.1. Materials
Materials used were: Hydroxyethyl cellulose (HEC) Natrosol® 250 M (Aqualon, Her-
cules Inc., Wilmington, DE, USA), Flufenamic acid, modification II (Kali-Chemie Pharma,
Hannover, Germany), Poly(D,L-lactic-co-glycolic acid) (lactic to glycolic acid ratio 50:50)
and a Mw distribution of 40,000–75,000 Da (Sigma Chemical Co., St. Louis, MO, USA),
caffeine (Sigma Chemical Co., St. Louis, MO, USA), Polyvinyl alcohol (PVA) Mowiol® 4-88
(Kuraray Specialities Europe GmbH, Frankfurt, Germany). Ringer solution, McIlvaine citric
acid phosphate buffer at different pH values, Phtalate buffer (pH 5.2), Phosphate buffer
(pH 6) were obtained from Merck, Darmstadt, Germany as well as phosphoric acid and
acetonitrile, n-octanol, propanol and potassium phosphate. Sodium hydroxide solution
(0.1 M), Hydrochloric acid (0.1 M) was bought from Grüssing GmbH, Filsum, Germany.
Methanol Chromasolv® for HPLC was from Sigma-Aldrich GmbH, Seelze, Germany. Ethyl
acetate came from Fluka Chemie GmbH, Bucks, Switzerland. Cellulose membrane MWCO
12,000–14,000 Da for permeation experiments were acquired from Medicell International
Ltd., London, LX, USA. Arabic gum (Caeser & Lorentz, Hilden, Germany), Gelatine A (Dt.
Gelatine Fabriken, Eberbach, Germany), LysoSensor™ Green DND-189 (Invitrogen GmbH,
Karlsruhe, Germany) were, as all other compounds, used as obtained from the suppliers.
2.2. Equipment
The HPLC system used for drug analysis was a ChromeleonTM Version 6.5 SP2, build
968 with a P580 Pump, an ASI-100 automated sample injector, a STH 585 Column oven
and an UVD 170S Detector from DionexSoftro GmbH (Germering, Germany). Franz diffu-
sion cell used was static (type 4G-01-00-15) from PermeGear (Riegelsville, PA, USA). NP
preparation made use of a high-speed homogenizer Ultra-Turrax® T25 (Jahnke & Kunkel
GmbH & Co. KG, Staufen, Germany) and Rotavapor® R-205 (Büchi, Flawil, Switzerland).
NP size characterization was performed with a Zetasizer® Nano (Malvern Instruments
GmbH, Herrenberg, Germany) and a Confocal laser scanning microscope (CLSM) MRC
1024 (BioRad/Carl Zeiss AG, Jena, Germany) and an atomic force microscopy (AFM) Di-
mension system, Digital Instruments (today Bruker Corporation, Billerica, MA, USA) was
used for visualization of the particles and the surrounding.
2.3. Nanoparticles Preparation and Characterization
PLGA loaded (FFA NP) and drug-free nanoparticles (DF-NP) were prepared by solvent
extraction method as described before [7]. In brief, thirty milligrams of FFA were dissolved
in 600 mg PLGA in 20 mL ethyl acetate. The organic phase was then added dropwise
into the same volume of an aqueous phase (20 mL), containing 1% of polyvinyl alcohol as
stabilizer, under stirring. The resulting o/w emulsion was homogenized with a high-speed
homogenizer at 13,500 rpm for 10 min. The amount of water was increased to 200 mL to
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precipitate the polymer/drug phase. Subsequently, the organic solvent was removed using
a rotating evaporator. Drug-free particles were prepared in the same way.
To also evaluate a potential size effect of the NP two different sizes were produced
(270 nm and 470 nm) by varying the homogenizing speed.
The PLGA NP were characterized using photon correlation spectroscopy (PCS) using a
Zetasizer Nano (Malvern, UK) and atomic force microscopy (AFM) using tapping mode at a
Dimension system, Digital Instruments (Bruker) [7]. The particles used had an entrapment
efficiency of 63.6% w/w FFA and PDI for all preparations were lower 0.1 indicating a narrow
size distribution. This was confirmed by AFM pictures also revealing the homogenous and
smooth surface structure of the particles. Those particles were already used in previously
published work [7] and therefore, will not be described in detail or discussed here again.
2.4. Microparticles from PLGA and Arabic Gum/Gelatine A
PLGA microparticles were obtained by emulsion technique based on the same compo-
sition as the nanoparticles but with lower homogenization speed (8000 rpm for 2 min).
The preparation of the arabic gum/gelatine. A microparticles as reference particles
was done by dissolving gelatine A in distilled water. Then several drops of n-octanol as
well as the dissolved arabic gum were added. Afterwards, distilled water at 50 ◦C was
added and the pH was adjusted to 4 using acetic acid. After overnight cooling, the particles
were re-dispersed in propanol for post-curing and dried.
2.5. Non-Buffered Gel Preparations
Hydroxyethyl cellulose (HEC) hydrogels of flufenamic acid (FFA HG) were prepared
from flufenamic acid dissolved in water. To accelerate dissolution a minimal amount
of sodium hydroxide solution was added (later neutralized adding hydrochloric acid)
under vigorous stirring. Afterwards, HEC was added in a proportion equivalent to 1.5%
(w/w) and stirred overnight until the polymer was completely swollen. The absence of
crystals was confirmed by microscopic inspection. For the preparation of non-buffered
gels containing the NP, the original NP suspension was concentrated. A total 20 mL of
freshly prepared nanoparticle suspensions was centrifuged at 2468× g for 5 min, 15 mL
of the supernatant was discarded and the particles re-suspended. Subsequently, their
drug content was determined and adjusted by dilution with distilled water to the required
concentration.
Flufenamic acid nanoparticle hydrogel (FFA NP HG) was prepared using a HEC
gel (3% w/w) which was mixed in a 1:1 ratio with a concentrated aqueous suspension of
the nanoparticles to obtain the same concentration as used for the drug containing gel
(FFA HG).
A hydrogel with incorporated drug-free nanoparticles (FFA HG + DF-NP) was pre-
pared using flufenamic acid and HEC concentration with doubled concentrations, prepared
as described for FFA HG and mixed with a concentrated drug-free nanoparticle suspension
in a proportion 1:1.
To the nanoparticle-containing gels, equal amounts of NaOH and HCl solutions as in
FFA HG were added. The presence and integrity of the spherical nanoparticles in the gel
was confirmed by AFM after deposition and drying on a flat surface as described earlier [7].
Permeation experiments were carried out in quadruplicate for FFA HG, FFA NP HG
and FFA HG + DF-NP, each with a drug concentration of 0.125 ± 0.006 mg/g.
2.6. Determination of the Saturation Concentration of Flufenamic Acid in Different Solutions
The analysis of the saturation concentration in different vehicles was performed as
follows: 500 mg of flufenamic acid were added into a volumetric flask (500 mL) and
Soerensen phosphate buffer (pH 6.0) and McIlvaine buffer solutions at pH values between
3.4 and 7.4 (for composition, please refer to [19]). All the different mixtures were stirred
at 500 rpm for 48 h at 32 ± 1 ◦C. Afterwards they were left to sediment for 12 h. Three
samples, of 10 mL each, were withdrawn from each flask and filtered through 0.2 µm-PTFE
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filter (OptiFlow) at 32 ± 1 ◦C. The first 7.5 mL were not used for analysis, and the last
2.5 mL were transferred to a separate flask. One milliliter of the filtered solution was
diluted to 100 mL with NaOH 0.05 M and analyzed by HPLC.
2.7. Buffered Gels Preparation with Soerensen Buffer
Buffered gels were prepared as described above using HEC and Soerensen phosphate
buffer pH 6.0 instead of water.
Permeation experiments were carried out at least in triplicate using FFA HG, FFA NP
HG and FFA HG + DF-NP, each with a drug concentration of (0.125 ± 0.006) mg/g. The pH
of the final preparations was in accordance with the respective buffer solution (±0.1 unit).
2.8. Flufenamic Acid Solutions and NP Suspensions
Non-Buffered Formulations
A concentrated solution of flufenamic acid (98.85 µg/mL) was prepared in NaOH
0.04 M.
Non-buffered solutions of flufenamic acid (FFA sol), non-buffered FFA-loaded nanopar-
ticle suspension (FFA NP), and non-buffered solutions with drug-free nanoparticles (FFA +
DF-NP) were prepared mixing the components from Table 1.
Table 1. Compositions of non-buffered flufenamic acid formulations.
Formulation Component FFA Sol FFA NP Suspension FFA Solution + DF-NP Suspension
FFA concentrated solution 40.464 mL – 40.464 mL
HCl 0.1 M 1.480 mL 1.480 mL 1.480 mL
NaOH 0.04 M – 40.464 mL –
FFA NP concentrated suspension – 25.536 mL –
DF-NP concentrated suspension – 25.536 mL
Deionized water to 100 mL 100 mL 100 mL
Buffered formulations with various MCIlvaine buffers:
One hundred milliliters of McIlvaine concentrated buffers were prepared by adjusting
the composition from Table 2.
Table 2. Composition of McIlvaine buffer solutions for buffered flufenamic acid preparations.
Solution Component pH 5.4 pH 6.4 pH 7.4
Citric acid monohydrate 0.2 M 44.7 31.4 9.8
Disodium phosphate dihydrate 0.4 M 55.3 68.6 90.2
Flufenamic acid solution (FFA sol), loaded nanoparticles (FFA NP) and buffered
formulations containing drug free nanoparticles were prepared as follows: Buffer solution
and water were mixed with the drug and stirred overnight to dissolve the drug. Afterwards,
concentrated nanoparticle suspension was added to the mixture (when corresponds). See
composition in Table 3.
Table 3. Composition of buffered flufenamic acid formulations.
Formulation Component FFA Sol FFA NP Suspension FFA Solution + DF-NP Suspension
FFA sol FFA NP FFA + DF-NP
Concentrated buffer 50.000 mL 50.000 mL 50.000 mL
Flufenamic acid 4000 µg 4000 µg
FFA NP concentrated suspension 25.536 mL
DF-NP concentrated suspension 25.536 mL
Deionized water to 100.000 mL 100.000 mL 100.000 mL
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To determine the drug concentration, the drug was extracted from all preparations and
diluted with NaOH 0.05 M and the samples were analyzed by HPLC. The concentration of
all liquid formulations was in the range of 37.6 ± 1.9 µg/mL.
2.9. Caffeine Solution and NP Suspension
Caffeine solution was prepared by dissolving 100 mg caffeine in 100 mL of water
under stirring overnight resulting in a concentration of 1 mg/mL (0.1%).
Caffeine solution with drug free PLGA nanoparticles was prepared by mixing a 0.2%
caffeine solution with a suspension of drug free PLGA nanoparticles in a ratio of 1:1 (v/v).
2.10. Skin Preparation
Excised human skin from Caucasian female patients, who had undergone abdominal
plastic surgery, was used. The procedure was approved by the Ethical Committee of the
Aerztekammer des Saarlandes, Saarbrücken, Germany (Code 204/08, 22 December 2008).
Adequate health and no medical history of dermatological disease were required. After
excision, subcutaneous fatty tissue was separated from whole dermis using skin pieces
10 × 10 cm by means of a scalpel. The cleaning of the skin surface was done with cotton
pads soaked with Ringer buffer, wrapped in aluminum foil, and stored in polyethylene
bags at −26 ◦C until use. Under these conditions no change in permeation characteristics
took place within six months [20,21].
Disks with a diameter of 25 mm were punched out from frozen skin, thawed, cleaned
with Ringer solution. These samples were used to prepare the heat separated epidermis
sheets then applied during permeation experiments in Franz diffusion cells.
2.10.1. Preparation of Heat Separated Epidermis
The epidermis was separated adding the cleaned skin disk after thawing in a water
bath of 60 ◦C for 90 s. Afterwards, the skin was transferred, dermal side down, on a filter
paper. Forceps were used to peel off the epidermal layer from the skin. Before use for
permeation experiments, the epidermal membrane was pre-hydrated for 1 h.
2.10.2. Reconstructed Human Epidermis Equivalents
The reconstructed human epidermis model SkinEthic RHE/L/17 (4.0 cm2) was pro-
vided by Laboratoire SkinEthic (Nice, France) and is described as an epidermal model
based on air-lifted culture of normal human keratinocytes for 17 days in chemically defined
medium on inert polycarbonate filters [22,23]. The morphology of SkinEthic RHE/L/17 is
highly similar to human tissue showing structures like stratum corneum, stratum gran-
ulosum and stratum spinosum. More details for the lipid composition and biochemical
markers of the reconstructed skin can be found in Netzlaff et al. [22].
For permeation experiments SkinEthic RHE/L/17) was punched out and used parallel
to heat separated epidermis.
2.10.3. Permeation Experiments
The permeation experiments were carried out using static Franz diffusion cells (FD-C)
with either heat-separated epidermis or reconstructed skin (SkinEthic). The skin membrane
was mounted on a cellulose membrane disk. The membrane was located between the
donor and receptor compartment of the FD-C. The donor phase was 0.75 mL gel or 1 mL
of drug solution or NP preparation for infinite dose experiments were used. As acceptor
served 12.1 mL of Soerensen phosphate buffer (pH 7.4). The donor compartment was
closed with sheets of aluminum foil and the system was kept at constant temperature
(32 ± 1) ◦C in a water bath. The acceptor was agitated at 500 rpm using a magnetic bar.
At predetermined time intervals, samples of 0.3 mL were withdrawn from the acceptor
compartment and replaced immediately with fresh buffer solution. Samples were collected
over 30 h and analyzed by HPLC. Integrity was checked visually by a magnifying glass
after mounting the skin specimen on the Franz diffusion cell.
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All samples were analyzed using the following HPLC conditions: Column LiChro-
spher 100 RP-18, 5 µm, 125 × 4 mm (Merck, Darmstadt, D); Mobile Phase: McIlvaine buffer
pH 2.2: Methanol (20:80); Flow rate: 1.2 mL/min; Wavelength: 284 nm; Injection volume:
20 µL; Retention time: (3.5 ± 0.2) min, lower limit of detection 50 ng/mL. This method
has been previously validated by Wagner et al. [24]. This method has been previously
validated by Wagner et al. [24].
Caffeine:
All samples were analyzed using the following HPLC conditions: Column LiChro-
spher 100 RP-18, 5 µm, 125 × 4 mm (Merck, Darmstadt, D); Mobile Phase: buffer pH 2.2
(composed of 1.16 mL phosphoric acid, 4.08 g potassium phosphate, water ad 1000 mL):
Acetonitrile (10:90 v/v); flow rate: 1.2 mL/min; Wavelength: 262 nm; Injection volume:
50 µL; Retention time: (3.1 ± 0.2) min. Lower limit of quantification: 30 ng/mL.
2.11. CLSM-Measurements
For determination of the local pH of the particle samples the pH of the particle
suspensions was roughly adjusted to pH = 7 using sodium hydroxide. Hereafter, 10 µL
suspension was mixed with 10 µL of a 0.1 mM LysoSensor™ solution. The mixture was
transferred onto a microscope slide and sealed with a cover slip using nail polish [25]. The
fluorescence measurements were performed using the 488 nm line of the argon/krypton
laser and a band pass filter (522/35) for each of the particle suspensions. Transmission
light images were taken using a conventional light bulb with the red channel of the CLSM
(MRC 1024 (BioRad/Carl Zeiss AG, Jena, Germany).
2.12. Statistical Evaluation
For statistical evaluation, SigmaStat 3.0.1 was used. ANOVA test was run using “all
pairwise comparison procedure” (Holm-Sidak method). All pairwise multiple comparison
procedures (Holm-Sidak method) were based on an overall significance level p < 0.05.
3. Results
3.1. Infinite Dose Permeation Experiments Using Unbuffered Hydrogels and Heat Separated
Human Epidermis
Infinite dose permeation experiments using unbuffered hydrogels containing dis-
solved flufenamic acid (FFA), either in presence or absence of drug-free NP or FFA encap-
sulated into nanoparticles (NPs), were performed in vitro to investigate the influence of
NPs on the dermal absorption.
As shown in Figure 1 an increase in the permeation of FFA was observed when the
drug was encapsulated into PLGA nanoparticles. The drug-loaded formulations were
statistically different from the pure drug in hydrogel or co-administered with the drug-free
particles in a drug-containing hydrogel. With respect to the influence of the particle size of
the particles no differences in skin penetration could be observed (statistically not different).
Particles with a mean diameter of 469 nm showed after 5 h the same permeability as the
286 nm particles. When drug-free nanoparticles were co-administered an intermediate
effect between dissolved drug and drug-loaded nanoparticles was observed which however,
did not reach statistical significance (Holm-Sidak test).
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to these considerations, permeation profiles showed a similar pattern with respect to those 
observed using human HSE (Figure 2). Drug-loaded NP showed a pronounced permea-
tion across the reconstructed, hair-follicle free skin. These results suggested that the fol-
licular pathway as proposed by Lademann and Toll [13] is not responsible for the in-
creased permeation induced by the nanosized preparations. As particles of these sizes are 
not expected to penetrate into/through skin this option can be ruled out [11,28]. Surpris-
ingly, DF-NP also show an effect on the drug permeation that was not expected. 
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3.2. Permeation Experiments Using Hydrogels and Reconstituted Human Epidermis
(Skinethic®)—Infinite Dose Regime
To elucidate the influence of hair follicles, experiments on reconstructed human
epidermal equivalents (SkinEthik®) were carried out. The SkinEthic® model is a human
reconstructed epidermal model, highly permeable [17,22,26,27] and devoid of hairs and
hair follicles. If the enhanced penetration of FFA encapsuled in NPs depends on the
accumulation of NPs in the hair follicle minor differences among the formulations would
be expected for the reconstituted human epidermis compared to human HSE. But in
contrast to these consider tions, permeation profil s showed a similar patte n with respect
to those observ d using human HSE (Figure 2). Drug-l aded NP showed a pronounced
permeation across the reconstructed, hair-follicle free skin. These results suggested that
the follicular pathway as proposed by Lademann and Toll [13] is not responsible for
the increased permeation induced by the nanosized preparations. As particles of these
sizes are not expected to penetrate into/through skin this option can be ruled out [11,28].
Surprisingly, DF-NP also show an effect on the drug permeation that was not expected.
In view of the sim lar penetration e hancement for natural and recons tuted (i.e.,
follicle-free) epidermis and the effect of the presence of unloaded particles with free drug
follicular penetration can be neglected. As an alternative effect, we hypothesized that
degradation of the nanoparticles generates a lower pH microenvironment around the
particles. This acidification was described for the matrix of microparticles before [14]. Such
a shift in pH would favor the non-ionized form of the drug, which is able to penetrate the
barrier easier than the ionic form. Degradation of PLGA is well documented [14,29–32].
We could also in the past visualize by AFM the degradation of the nanoparticles [32]. To
substantiate this hypothesis, the following experiments were carried out to elucidate if
the pH generated by the degradation of PLGA NPs has any influence on the permeation
through the epidermal barrier.
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As for instance concentration gradients will influence the permeation behavior, the
saturation concentrations of flufenamic acid at different pH values were determined.
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Table 4. Saturation concentration and ionized percentage of flufenamic acid in different solvents at









Water 5.8 ± 0.8 n.d. n.d.
Soerensen buffer pH 6.0 29.4 ± 0.4 99.21 0.79
McIlvaine buffer
pH 3.4 1.8 ± 0.2 24.00 76.00
pH 4.4 5.6 ± 0.5 75.97 24.03
pH 5.4 43.1 ± 1.8 96.93 3.07
pH 6.4 383.4 ± 14.2 99.68 0.32
pH 7.4 2896.1 ± 55.9 99.97 0.03
Soerensen buffer pH 7.4 * 2059.5 ± 21.6 99.97 0.03
* data were taken from [33]. n.d.: not determined.
Table 4 shows very clearly that the concentration of saturation of flufenamic acid
decreases with lower pH value, however, on the other hand the non-ionized form is
enhanced. As the non-ionized form is responsible for passing the Stratum corneum barrier
a higher permeation occurs.
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3.4. Infinite Dose Permeation Studies Using Buffered Hydrogels and Heat Separated
Human Epidermis
In a first approach, the influence of buffering of the hydrogel preparation was investi-
gated. In this way the conditions and the amount of ionized, non-ionized drug was fixed.
Permeation experiments with hydrogels buffered with Soerensen phosphate buffer pH
6.0 and the same concentration, as used for previous experiments, were done. Soerensen
phosphate buffer was selected due to the compatibility with the gel forming agent (hy-
droxyethyl cellulose) and the pH at the skin’s surface. When hydrogels buffered to pH 6.0
were examined, differences in permeation diminished in comparison to the unbuffered
preparations (Figure 3). Based on these data we concluded that the buffer compensates the
effect of the nanoparticles on skin permeation.
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3.5. Permeation Studies with Non-Buffered and Buffered Solutions in Presence and Absence
of Nanoparticles
To rule out the influence of the gel forming agent on the skin permeation FFA solutions
with or without unloaded NPs and FFA-loaded nanoparticles in suspension in a non-
buffered and buffered form at different pH values were applied. For all these experiments
skin from one donor was used.
For non-buffered systems (see Figure 4A) the highest permeation occurred using
FFA-loaded nanoparticles, an intermediate effect was obtained when non-loaded particles
were added to FFA in solution and the lowest permeation was found for ‘FFA only’ in
solution. These results display the same rank order already established for FFA hydrogel
formulations (Figure 1) suggesting that the gel forming agent has no influence on the
permeation of FFA through the dermal barrier.
Looking at the buffered systems, it can be clearly seen that the differences dimin-
ished between FFA in solution without or with drug free NPs and FFA encapsulated in
PLGA-NPs. This is true independent of the tested pH. Moreover, when comparing the
preparations at different pH values, a decreased permeation was displayed if pH value
rose. This is in accordance with physicochemical models of skin permeation for lipophilic
substances that non-ionized forms preferentially permeate the lipophilic pathway of the
stratum corneum resulting in an enhanced absorption [34].
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Figure 4. Permeation profiles obtained for human heat separated epidermis using flufenamic acid solution (FFA sol),
FFA solution plus drug-free nanoparticles (FFA sol + DF-NP susp) and drug-loaded nanoparticles (FFA NP susp). The
formulations were applied as non-buffered preparations (NB, (A)) and buffered preparations at different pH values (pH 5.4
(B), pH6.4 (C), pH 7.4 (D)). Concentration of flufenamic acid 37.6 ± 1.9 µg/mL.
3.6. Permeation Studies with Caffeine
To further test our pH hyp thesis, skin ermeation studies with caffeine ave been
conducte . It was expected that no differences in permeation will be found if aqueous
solutions of caffeine without or with drug free NPs are used as the drug should not be
affected by potential pH changes. As seen from Figure 5 no difference was displayed
between caffeine in solution and caffeine in solution with addition of drug-free PLGA
NP. These findings corroborate our hypothesis that change of ionization by an acidic
surrounding of the NPs is responsible for the enhancement effects for FFA permeation.
Unfortunately, no PLGA NP loading the hydrophilic caffeine could be prepared using
the same preparation approach as used for flufenamic acid (solvent extraction method).
The hydrophilic caffeine could not be dissolved in the organic solvent used for PLGA. Thus,
an encapsulation of reasonable mount in the PLGA particles was not possible. To achieve
such an incorporation the preparation method would have to be modified hampering the
conclusion due changing several properties of the particulate system at the time. Thus, a
direct comparison of this experimental condition was not possible.
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F rthermore, there are reports in literature on the effect of α-hydroxy acids which can
reduce the Stratum corneum’s cohesion, allowing to incr ase permeation f drugs across
t e skin. For example, Sebastiani et al. [35] have studie the effects of lactic acid on the skin
permeation using rabbit skin. Three drugs offering different physicochemical properties
were investigated demonstrating that only the passive permeation of ibuprofen, an anionic
drug (characteristic present also in flufenamic acid), was affected by the presence of lactic
acid. It was found that this led to a clear increase in permeation. Consequently, also if the
different pathways remained unchanged, the partitioning from the formulation into the
skin was increased [35].
3.7. Investigation of the pH in the Surrounding of the Particles’ Surface
To investigate the pH of the micro-surrounding of the particles’ experiments using
confocal laser scanning microscopy were performed. As the pH change is linked to the
hydrolysis of the NP material it might take place only in the very close (nano-) environment
of the particles. However, the optical transfer function of the microscope will limit the
resolution. Thus in the micrographs objects smaller than the resolution will be depicted at a
dimension equal to the so-called “Airy disc” [36]. For the application of fluorescence-based
methods, such as pH-sensitive dyes, the local resolution is therefore also limited and might
exceed the extension of the area covered by the particles and the area where the pH change
might take place. To overcome these problems regarding the particles, we used PLGA
microparticles in the range of several micrometers. This facilitated the investigation of the
pH on and close to the surface. As a negative control Arabic gum/gelatine A microparticles
were deployed. For pH analysis the dye LysoSensor®green enabled us to visualize if
different pH values are established even though the precise local determination is not
accessible. The LysoSensor® dyes are known as acidotropic compounds. For pH-values
above the pKa the dye is unprotonated and the fluorescence is quenched [37]. There-
fore, the dye chosen exhibits practically no fluorescence at neutral pH (condition apart
from the particles). In acidic environment the molecules are protonated and the fluores-
cence quenching is relieved; light emission is strongly increased. The images depicted in
Figure 6D reveal a strong fluorescence around the PLGA microparticles and indicate that
our assumption regarding the particles’ pH is correct. Image 6A reveals the presence of the
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Arabic gum/gelatine A particles in transmission light whereas in Figure 6B the fluorescence
channel is displayed. It can be seen that with those particles no change of the pH and
thus no fluorescence is connected. For the PLGA micro- and nanoparticles experiments
the background fluorescence was reduced by pre-setting the pH to approximately 7 (The
situation is sketched in Figure 6C,F: particles in a slightly fluorescent solvent). The result
changes completely exposing the PLGA particles to the same surrounding and measuring
conditions as described before. An intense fluorescent signal (Figure 6D,E) was observed.
As the location of the fluorescence from the nanoparticles cannot be detected due to the
resolution limit of the microscope, PLGA microparticles were used to demonstrate the
localization of the fluorescence. The microparticle fluorescence discloses that the light
is emitted from/or close to the surface of the particles. The inner particle shows fading
fluorescence indicating the absence of fluorescent molecules. For the PLGA nanoparticles
the fluorescence is observed as well but due to their size only fluorescent spots are visible
which was highlighted by the inverted color coding (Figure 6E). The results clearly indicate
the different pH values at the particles’ surface or close environment compared to other
particles.





Figure 6. Fluorescence micrographs obtained after dispersing different particle fractions into pH sensor solution. Trans-
mission light image were taken to identify Arabic gum/gelatine A microparticles (A) and the corresponding fluorescence 
image (B). PLGA microparticles show green fluorescence localized at the surface of the particles or the close surrounding 
(D). For nanoparticles, fluorescent spots were detected (E). For highlighting the particles position the color coding was 
inverted leading to a pink background with block spots representing the fluorescent nanoparticles. The sketches should 
illustrate the experimental conditions (C,F). 
Consequently, a pH-dependent change of drug partitioning into the stratum 
corneum appears as most plausible explanation for the observed skin permeation en-
hancement under influence of PLGA nanoparticles. The changed partitioning might result 
from the local acidic environment around the nanoparticles due to the degradation and a 
raised fraction of unionized drug. Its lipophilicity and ability to dissociate at physiological 
skin pH make flufenamic acid a good candidate still, for improved delivery through the 
skin by such formulations. 
4. Conclusions 
The increased permeation of flufenamic acid through the epidermis from a non-buff-
ered vehicle indicates that PLGA nanoparticles may improve the transdermal delivery of 
FFA. According to our data, particles of this biodegradable polymer may induce a “co-
rona” of low pH that influences the ionization state of the drug in the micro surroundings 
of the particles. Therefore, the drug may better penetrate across the skin barrier under 
such conditions, which may be used advantageously for improved topical delivery of 
acidic drugs, such as e.g., non-steroidal antirheumatic, without using any additional per-
meation enhancers. 
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local acidic environment around the nanoparticles due to the degradation and a raised
fraction of unionized drug. Its lipophilicity and ability to dissociate at physiological skin
pH make flufenamic acid a good candidate still, for improved delivery through the skin by
such formulations.
4. Conclusions
The increased permeation of flufenamic acid through the epidermis from a non-
buffered vehicle indicates that PLGA nanoparticles may improve the transdermal delivery
of FFA. According to our data, particles of this biodegradable polymer may induce a
“corona” of low pH that influences the ionization state of the drug in the micro surroundings
of the particles. Therefore, the drug may better penetrate across the skin barrier under such
conditions, which may be used advantageously for improved topical delivery of acidic
drugs, such as e.g., non-steroidal antirheumatic, without using any additional permeation
enhancers.
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